Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine
- PMID: 11683683
- DOI: 10.1046/j.1365-2036.2001.01102.x
Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine
Abstract
The thioguanine derivative, azathioprine, is a prodrug of 6-mercaptopurine that is further metabolized by various enzymes present in the liver and gut. Azathioprine and 6-mercaptopurine have been used in the treatment of inflammatory bowel disease, i.e. ulcerative colitis and Crohn's disease, for more than 30 years. However, widespread use of azathioprine or 6-mercaptopurine in inflammatory bowel disease is of more recent origin, the primary reason being a long-standing debate on the efficacy of these agents in inflammatory bowel disease. Both drugs are slow acting, which is why clinical efficacy cannot be expected until several weeks or even months of treatment have elapsed. Consequently, azathioprine and 6-mercaptopurine have no place as monotherapy in the treatment of acute relapsing inflammatory bowel disease. Today, azathioprine and 6-mercaptopurine are the most commonly used immunomodulatory drugs in the treatment of inflammatory bowel disease. Their clinical effects are probably identical, although their exact mode of action is still unknown. The mode of action of azathioprine is thought to be multifactorial, including conversion to 6-mercaptopurine (which acts as a purine antimetabolite), possible blockade of thiol groups by alkylation, inhibition of several pathways in nucleic acid biosynthesis (preventing proliferation of cells involved in the determination and amplification of the immune response) and damage to DNA through the incorporation of thiopurine analogues. However, 6-thioguanine nucleotides may accumulate in toxic doses in myeloid precursor cells, resulting in life-threatening myelosuppression. Azathioprine and 6-mercaptopurine are further known to alter lymphocyte function, reduce the number of lamina propria plasma cells and affect natural killer cell function. The purpose of this comprehensive review is to suggest guidelines for the application of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease.
Similar articles
-
Azathioprine or 6-mercaptopurine for inflammatory bowel disease: do risks outweigh benefits?Dig Liver Dis. 2000 Aug-Sep;32(6):518-31. doi: 10.1016/s1590-8658(00)80010-9. Dig Liver Dis. 2000. PMID: 11057928 Review.
-
Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease.Inflamm Bowel Dis. 2004 Jul;10(4):339-45. doi: 10.1097/00054725-200407000-00003. Inflamm Bowel Dis. 2004. PMID: 15475740 Clinical Trial.
-
Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety.Clin Gastroenterol Hepatol. 2004 Sep;2(9):731-43. doi: 10.1016/s1542-3565(04)00344-1. Clin Gastroenterol Hepatol. 2004. PMID: 15354273 Review.
-
Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.Dig Liver Dis. 2005 Jun;37(6):407-17. doi: 10.1016/j.dld.2004.12.013. Dig Liver Dis. 2005. PMID: 15893279 Review.
-
Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives.J Crohns Colitis. 2018 Apr 27;12(5):610-620. doi: 10.1093/ecco-jcc/jjx181. J Crohns Colitis. 2018. PMID: 29293971 Review.
Cited by
-
FK506 microparticles mitigate experimental colitis with minor renal calcineurin suppression.Pharm Res. 2005 Feb;22(2):193-9. doi: 10.1007/s11095-004-1186-2. Pharm Res. 2005. PMID: 15783066
-
How important is onset of action in ulcerative colitis therapy?Drugs. 2005;65(15):2069-83. doi: 10.2165/00003495-200565150-00001. Drugs. 2005. PMID: 16225364 Review.
-
Treatments of inflammatory bowel disease toward personalized medicine.Arch Pharm Res. 2021 Mar;44(3):293-309. doi: 10.1007/s12272-021-01318-6. Epub 2021 Mar 24. Arch Pharm Res. 2021. PMID: 33763844 Review.
-
Immunosuppression: towards a logical approach in liver transplantation.Clin Exp Immunol. 2005 Jan;139(1):2-10. doi: 10.1111/j.1365-2249.2005.02662.x. Clin Exp Immunol. 2005. PMID: 15606606 Free PMC article. Review.
-
Successful azathioprine treatment with metabolite monitoring in a pediatric inflammatory bowel disease patient homozygous for TPMT*3C.Yonsei Med J. 2013 Nov;54(6):1545-9. doi: 10.3349/ymj.2013.54.6.1545. Yonsei Med J. 2013. PMID: 24142665 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources